FindTrial
Sign In

Myoinositol a new treatment option in Polycystic Ovarian Syndrome versus metformin-the conventional drug.

Comparative Study of Metformin versus Myoinositol in Polycystic Ovarian Syndrome patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/09/021403
Enrollment
94
Registered
2019-09-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: METFORMIN: Metformin is an oral biguanide,and first insulin sensetising drug to be used in pcos,it modulated endothelin function causes weight loss and improves ovarian function and red

Sponsors

Swati Jain
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: •All the females of age group 15-40 years fulfilling the Rotterdamâ??s criteria.3 •According to Rotterdamâ??s Criteria the affected must have :(atleast 2 out of 3) (A) Oligovulation and /or anovulation . (B)Hyperandrogenism(clinical/or biochemical) . (C)Polycystic-ovaries,identified sonographically.

Exclusion criteria

Exclusion criteria: 1.Patients already on other drug treatment for PCOS (like oral contraceptive pills) 2.Deranged kidney or liver function tests 3. Thyroid disorders 4.Known hypersensitivity to drugs 5. Galactorrhoea 6. Patient on any infertility treatment/fertility enhancing drugs 7. Established cases of diabetes mellitus

Design outcomes

Primary

MeasureTime frame
â?¢To compare the EFFECTIVENESS of Metformin versus Myoinositol in Polycystic ovarian syndrome patients in terms of weight reduction, Ferriman Gallwey score, menstrual cycle pattern after 3 months. After 6 months, complete radiological, biochemical and anthropometric reassessment will be done.Timepoint: Follow up will be done at 3rd and 6th month—

Secondary

MeasureTime frame
1.To identify patients of PCOS patients by Rotterdamâ??s criteria. 2.To study the role of Metformin in PCOS patients in terms of clinical improvement ,biochemical correction and radiological parameters . 3.To study the role of Myoinositol in PCOS patients in terms of clinical improvement,biochemical correction and radiological parameters. 4.Comparing Metformin versus Myoinositol in terms of clinical ,biochemical and radiological correction along with side effects. Timepoint: Follow up will be done at 3rd and 6th month—

Countries

India

Contacts

Public ContactDr Rehana Najam

Teerthanker Mahaveer Medical College

rehananajam01@gmail.com9837291920

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026